

Cardiovascular system damage in the late-onset Pompe disease
https://doi.org/10.21508/1027-4065-2023-68-3-83-91
Abstract
The article presents a clinical case of metabolic hypertrophic cardiomyopathy against the background of a late-onset form of Pompe disease, illustrating the difficulties of differential diagnostic search for the cause of the disease. The clinical, laboratory and genetic aspects of the diagnosis of Pompe disease are highlighted. The features of laboratory diagnostics, the difficult path to the correct diagnosis and the appointment of enzyme replacement therapy are discussed. Much attention is paid to the clinical symptoms of the disease — the most significant damage to the cardiovascular system, there is no damage to the musculoskeletal sphere. Clinical picture of late Pompe disease is presented: cardiac rhythm and conduction disorders (ventricular preexcitation syndrome — multiple additional atrioventricular fenestrations), unstable ventricular tachycardia, supraventricular tachycardia, sinus node weakness syndrome. Considered approaches to the prevention of sudden cardiac death the patient underwent surgical treatment: radiofrequency ablation, endocardial implantation of a cardioverter defibrillator. Pathogenetic therapy for Pompe disease has been started.
About the Authors
I. V. LeontievaRussian Federation
Moscow
Yu. S. Isaeva
Russian Federation
Moscow
I. M. Miklashevich
Russian Federation
Moscow
S. A. Thermosesov
Russian Federation
Moscow
References
1. Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014; 35: 2733–2779. DOI: 10.1093/eurheartj/ehu284
2. Maron B., Rowin E., Casey S., Lesser J., Garberich R. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation 2016; 133(1): 62–73. DOI: 10.1161/CIRCULATIONAHA.115.017633
3. Arad M., Maron B.J., Gorham J.M., Johnson W.H. Jr., Saul J.P., Perez-Atayde A.R. et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352: 362–372. DOI: 10.1056/NEJMoa033349
4. Leontyeva I.V. Differential diagnosis of hypertrophic cardiomyopathy. Rossiyskiy Vestnik Perinatologii i Pediatrii 2017; 62(3): 20–31. (in Russ.)
5. Lopez-Sainz A., Dominguez F., Lopes L.R., Ochoa J.P., Barriales-Villa R., Climent V. et al. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis J Am Coll Cardiol 2020; 76(2): 186–197. DOI: 10.1016/j.jacc.2020.05.029
6. Cenacchi G., Papa V., Pegoraro V., Marozzo R., Fanin M., Angelini C. Danon disease: Review of natural history and recent advances. Neuropathol Appl Neurobiol 2020; 46(4): 303–322. DOI: 10.1111/nan.12587
7. Llerena J.C., Nascimento O.J., Oliveira A.S., Dourado M.E., Marrone C.D., Siqueira H.H. et al. Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease Arq Neuropsiquiatr 2016; 74(2): 166–176. DOI: 10.1590/0004–282X20150194
8. Taverna S., Cammarata G., Colomba P., Sciarrino S., Zizzo C., Francofonte D. et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging 2020; 15: 15856–15874. DOI: 10.18632/aging.103794
9. Sun A. Lysosomal storage disease overview. Ann Transl Med 2018; 6: 476. DOI: 10.21037/ATM.2018.11.39
10. Schoser B. Pompe disease: what are we missing? Ann Transl Med 2019; 7(13): 292. DOI: 10.21037/atm.2019.05.29
11. Reuser A.J., van der Ploeg A.T., Chien Y.H., Llerena J. Jr., Abbott M.A., Clemens P.R. et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe registry. Hum Mutat 2019; 40: 2146–2164. DOI: 10.1002/humu.23878
12. Kutsev S.I., Nikitin S.S., Namazova-Baranova L.S., Baranov A.A., Vashakmadze N.D., Artemyeva S.B. Clinical recommendations Pompe disease in children. Clinical guidelines, 2019. (in Russ.) https://www.pediatr-russia.ru/information/klin-rek/deystvuyushchie-klinicheskie-rekomendatsii/Болезнь%20Помпе%20КР%202020.pdf / Ссылка активная на 04.05.2023.
13. Dasouki M., Jawdat O., Almadhoun O., Pasnoor M., McVey A.L., Abuzinadah A. et al. Pompe disease: literature review and case series. Neurol Clin 2014; 32: 751–776. DOI: 10.1016/j.ncl.2014.04
14. Lim J.A., Li L., Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 2014; 6: 177. DOI: 10.3389/fnagi.2014.00177
15. Kishnani P.S., Steiner R.D., Bali D., Berger K., Byrne B.J., Case L.E. et al. Pompe disease diagnosis and management guideline. DOI: 10.1097/01.gim.0000218152.87434.f3
16. Toscano A., Rodolico C., Musumeci O. Multisystem late onset pompe disease (LOPD): an update on clinical aspects. Ann Transl Med 2019; 7(13): 284. DOI: 10.21037/atm.2019.07.24
17. Preisler N., Lukacs Z., Vinge L., Madsen KL., Husu E., Hansen RS. et al. Late-onset pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Mol Genet Metab 2013; 110: 287–289. DOI: 10.1016/j.ymgme.2013.08.005
18. Semyachkina A.N., Sukhorukov V.S., Bukina T.M., Yablonskaya M.I., Merkurieva E.S., Kharabadze M.N. et al. Glycogen storage disease type II (Pompe disease) in children. Rossiyskiy Vestnik Perinatologii i Pediatrii 2014; 4; 49–55. (in Russ.)
19. Musumeci O., Marino S., Granata F., Morabito R., Bonanno L., Brizzi T. et al. Central nervous system involvement in late-onset pompe disease: clues from neuroimaging and neuropsychological analysis. Eur J Neurol 2019; 26: 442–e35. DOI: 10.1111/ene.13835
20. Maron B.J., Roberts W.C., Ho C.Y., Kitner C., Haas T.S., Wright G.B. et al. Profound left ventricular remodeling associated with LAMP2 cardiomyopathy. Am J Cardiol 2010; 106: 1194–1196. DOI: 10.1016/j.amjcard.2010.06.035
21. Sankaranarayanan R., Fleming E., Garratt C. Mimics of Hypertrophic Cardiomyopathy — Diagnostic Clues to Aid Early Identification of Phenocopies. Arrhythm Electrophysiol Rev 2013; 2(1): 36–40. DOI: 10.15420/aer.2013.2.1.36
22. Angelini C., Semplicini C., Ravaglia S., Bembi B., Servidei S., Pegoraro E. et al. Italian GSDII Group Observational clinical study in juvenileadult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012; 259: 952
Review
For citations:
Leontieva I.V., Isaeva Yu.S., Miklashevich I.M., Thermosesov S.A. Cardiovascular system damage in the late-onset Pompe disease. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2023;68(3):83-91. (In Russ.) https://doi.org/10.21508/1027-4065-2023-68-3-83-91